Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc to Present Clinical Update for SRP-5051 Conference Call Transcript

Dec 07, 2020 / 01:30PM GMT
Release Date Price: R$38.47
Operator

Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics Clinical Update MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference Call and Webcast. (Operator Instructions) As a reminder, today's program is being recorded.

At this time, I'll turn the call over to Doug Ingram, President and CEO, for opening remarks.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you very much for that, and thank you all for joining us this morning.

This morning, we are pleased to report our interim results from MOMENTUM, which is our multi-ascending dose study for our second-generation PPMO RNA therapy, SRP-5051, at 20 mgs per kg.

Now we will be making some statements and potential predictions about the future this morning, so-called forward-looking statements. So please refer to our public filings for a discussion of the inevitable risks and uncertainties that are attendant when one makes forward-looking statements.

And with no further delay, I will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot